Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Xikang Cloud Hospital Holdings Inc.
熙康雲醫院控股有限公司

(formerly known as Neusoft Xikang Holdings Inc. 東軟熙康控股有限公司)
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 9686)

DISCLOSEABLE TRANSACTION
SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCT

Reference is made to the announcement of the Company dated 13 June 2025 in relation to the use of the idle Proceeds for cash management.

Reference is also made to the announcement of the Company dated 10 March 2025 in relation to the subscription by the Company for Wealth Management Product in an amount of US$15,000,000 from Shenwan Hongyuan Financial Products (the "**Previous Subscription**"). The Wealth Management Product under the Previous Subscription has matured on 13 March 2026, with a total amount of principal and returns of US$15,409,726. The Board announces that on 13 March 2026, the Company continued to subscribe for Wealth Management Product from Shenwan Hongyuan Financial Products with the principal and returns from the Previous Subscription (i.e. US$15,409,726) as the consideration.

IMPLICATIONS UNDER THE LISTING RULES

As one or more applicable percentage ratios calculated pursuant to Rule 14.07 of the Listing Rules in respect of the Subscription exceed 5% but are lower than 25%, the Subscription constitutes a discloseable transaction of the Company under relevant requirements of Chapter 14 of the Listing Rules, and is subject to the relevant reporting and announcement requirements of the Listing Rules but exempt from the Shareholders' approval requirement.

THE SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCT

Reference is made to the announcement of the Company dated 13 June 2025 in relation to the use of the idle Proceeds for cash management.

Reference is also made to the announcement of the Company dated 10 March 2025 in relation to the Previous Subscription. The Wealth Management Product under the Previous Subscription has matured on 13 March 2026, with a total amount of principal and returns of US$15,409,726. The Board announces that on 13 March 2026, the Company continued to subscribe for Wealth Management Product from Shenwan Hongyuan Financial Products with the principal and returns from the Previous Subscription (i.e. US$15,409,726) as the consideration. The subscription amount under the Subscription is funded from the idle Proceeds from the Global Offering, along with the returns generated.

The major terms and conditions of the Subscription are summarised below:

(1)	Date of subscription:	13 March 2026
(2)	Name of product:	Fund Portfolio Linked Note
(3)	Parties to the agreement:	(i) Shenwan Hongyuan Financial Products, as the issuer; (ii) Shenwan Hongyuan (H.K.), as the guarantor; and (iii) the Company, as the subscriber
(4)	Type of product:	Guaranteed structured note
(5)	Risk level of product (internal risk rating by the issuer):	Low
(6)	Principal amount subscribed:	US$15,409,726
(7)	Term of investment:	One year, subject to early redemption at any time
(8)	Annualised rate of return:	Expected to be 2.25%-3.75%, subject to the actual return rate of the underlying assets
(9)	Investment scope of the Product:	Underlying subject of cash management products

REASONS FOR AND BENEFITS OF THE SUBSCRIPTION

The Directors are of the view that (i) the Subscription can improve the idle Proceeds utilization efficiency and increase income from idle Proceeds; (ii) low-risk and diversified investments in cash management products that are subject to early redemption at any time are conducive to enhancing the safety and flexibility of cash management; and (iii) reasonable utilisation of the temporarily idle Proceeds to realize value preservation and appreciation of the Proceeds will protect the interests of the Shareholders of the Company, and will not affect the Group's working capital position or operation. Accordingly, the Directors consider that the Subscription is on normal commercial terms which are fair and reasonable and in the interests of the Company and the Shareholders as a whole.

INFORMATION ON THE PARTIES

The Company

The Company has established a cloud hospital network that connects local governments, medical institutions, patients and insurers to enable equitable access to medical resources and more effective and efficient delivery of medical services, nursing services and health management services.

Shenwan Hongyuan Financial Products and Shenwan Hongyuan (H.K.)

To the best of the Directors' knowledge, Shenwan Hongyuan Financial Products (wholly owned by Shenwan Hongyuan (H.K.)) is a company incorporated in the British Virgin Islands with limited liability, and is principally engaged in provision of financing services. Shenwan Hongyuan (H.K.) is a company incorporated in Hong Kong with limited liability and is principally engaged in the provision of financial services, and the shares of which are listed on the main board of the Stock Exchange (stock code: 218).

To the best of the Directors' knowledge, information and belief and having made all reasonable enquiries, Shenwan Hongyuan Financial Products, Shenwan Hongyuan (H.K.) and their respective ultimate beneficial owners are third parties independent of the Company and its connected persons.

IMPLICATIONS UNDER THE LISTING RULES

As one or more applicable percentage ratios calculated pursuant to Rule 14.07 of the Listing Rules in respect of the Subscription exceed 5% but are lower than 25%, the Subscription constitutes a discloseable transaction of the Company under relevant requirements of Chapter 14 of the Listing Rules, and is subject to the relevant reporting and announcement requirements of the Listing Rules but exempt from the Shareholders' approval requirement.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following terms shall have the following meanings:

"Board"	the board of Directors
"Company"	Xikang Cloud Hospital Holdings Inc. (熙康雲醫院控股有限公司), an exempted company incorporated in the Cayman Islands with limited liability on 12 May 2011, the shares of which are listed on the Main Board of the Stock Exchange
"connected person(s)"	has the meaning ascribed to it under the Listing Rules
"Director(s)"	the director(s) of the Company
"Global Offering"	has the same meaning as ascribed to it as set out in the prospectus of the Company dated 18 September 2023
"Group"	the Company, its subsidiaries and the consolidated affiliated entities controlled through contractual arrangements

"Hong Kong"	Hong Kong Special Administrative Region of the PRC
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange
"percentage ratios"	have the same meaning as ascribed to it under the Listing Rules
"PRC"	the People's Republic of China, for the purpose of this announcement only, except where the context otherwise requires, excluding Hong Kong, Macao Special Administrative Region and Taiwan of the PRC
"Proceeds"	proceeds from the Global Offering
"Wealth Management Product"	Fund Portfolio Linked Note issued by Shenwan Hongyuan Financial Products, a wealth management product of guaranteed structured note
"Shareholder(s)"	holder(s) of the shares of the Company
"Shenwan Hongyuan Financial Products"	Shenwan Hongyuan Financial Products Company Limited
"Shenwan Hongyuan (H.K.)"	Shenwan Hongyuan (H.K.) Limited
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"Subscription"	the subscription by the Company for the Wealth Management Product from Shenwan Hongyuan Financial Products , with its principal terms set out in this announcement
"US$"	United States dollars, the lawful currency of the United States of America
"%"	per cent

By order of the Board
Xikang Cloud Hospital Holdings Inc.
Dr. LIU Jiren
Chairman and Non-Executive Director

The PRC, 13 March 2026

As at the date of this announcement, the Board of the Company comprises Ms. ZONG Wenhong as an executive Director; Dr. LIU Jiren, Mr. XU Hongli, Dr. WANG Nan and *Mr. PU Chengchuan as non-executive Directors; and Dr. CHEN Yan, Dr. QI Guoxian and Dr. YIN Guisheng as independent non-executive Directors.*